The study titled “TEMPO trial: Daily Temozolomide for Elderly patients with unmethylated MGMT- Promoter newly diagnosed GliOblastoma” explores daily dosing of low-dose Temozolomide in patients aged 65 years or older in an approach that may be associated with longer survival and acceptable side effects compared to today’s usual approach. 

“Glioblastoma is the most common and aggressive type of primary brain cancer, and it disproportionately affects older adults, who are often underrepresented in clinical trials. Our study explores a simple, low-dose chemotherapy approach that may improve treatment outcomes while preserving quality of life. If successful, this widely available regimen could expand access to care and offer a much-needed option for patients with limited alternatives, with potential for broad global implementation,” says Dr. Santin

Brain Cancer Canada values this work for its structured approach to exploring learning more about a drug already in use for 20 years. By re-thinking today’s dosing regimens, this study can uncover whether a change in approach might improve patients’ experiences and offer new hope for longer survival without introducing new and possibly unacceptable side effects.

This research grant was made possible through community fundraising, including Carlos Pimentel's Himalaya's Trek Research, David Emer Legacy Fund, Marino DiRienzo Legacy Fund, Ride for Don, Wong Strong, and Joe Cortese's Support the Blazer.